PDCD1 and hepatocellular carcinoma: In the CheckMate-040 trial,8 among all of the patients with advanced HCC who were treated with nivolumab, a programmed cell death protein-1 inhibitor, 51 had HBV and 50 had HCV; no patients were found to have signs of hepatitis reactivation.